{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:44:27Z","timestamp":1793295867064,"version":"4.5.0"},"reference-count":72,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"G. d\u2019Annunzio University, Chieti"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Autism spectrum disorder (ASD) is a neurological disease and lifelong condition. The treatment gap in ASD has led to growing interest in alternative therapies, particularly in phytocannabinoids, which are naturally present in Cannabis sativa. Studies indicate that treatment with cannabidiol (CBD)-rich cannabis may possess the potential to improve fundamental ASD symptoms as well as comorbid symptoms. This systematic review aims to assess the safety and efficacy of CBD-rich cannabis in alleviating the symptoms of ASD in both children and adults, addressing the treatment gap and growing interest in CBD as an alternative treatment. A comprehensive literature search was conducted in February 2024 using the PUBMED and Scopus databases while following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search focused on studies from 2020 onward involving human populations diagnosed with ASD and treated with CBD. Four studies met the inclusion criteria and were analyzed. The review included 353 participants with ASD from studies conducted in Israel, Turkey, and Brazil. The studies varied in design, sample size, dose, and treatment duration. Dosages of CBD were often combined with trace amounts of THC. Improvements were noted in behavioral symptoms, social responsiveness, and communication, but cognitive benefits were less consistent. Adverse effects ranged in severity. Mild effects such as somnolence and decreased appetite were common, while more concerning effects, including increased aggression, led to some cases of treatment discontinuation. CBD-rich cannabis shows promise in improving behavioral symptoms associated with ASD. However, variations in study designs, dosages, and outcome measures highlight the need for standardized assessment tools and further research to understand pharmacological interactions and optimize treatment protocols. Despite the mild adverse effects observed, larger, well-controlled trials are necessary to establish comprehensive safety and efficacy profiles.<\/jats:p>","DOI":"10.3390\/ijms252212453","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T07:02:58Z","timestamp":1732086178000},"page":"12453","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Evolving Role of Cannabidiol-Rich Cannabis in People with Autism Spectrum Disorder: A Systematic Review"],"prefix":"10.3390","volume":"25","author":[{"given":"Bilal","family":"Jawed","sequence":"first","affiliation":[{"name":"Unit of Clinical Pathology and Microbiology, Miulli Generale Hospital, LUM University, 70021 Acquaviva delle Fonti, Italy"},{"name":"PhD Program in Science and Technology in Sustainable Development, G.d\u2019Annunzio University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8818-3731","authenticated-orcid":false,"given":"Jessica Elisabetta","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Innovative Technology in Medicine and Dentistry, G.d\u2019Annunzio University, 66100 Chieti, Italy"},{"name":"PhD Program in Innovative Technologies in Clinical Medicine and Dentistry, G.d\u2019Annunzio University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8334-0577","authenticated-orcid":false,"given":"Riccardo","family":"Pulcini","sequence":"additional","affiliation":[{"name":"PhD Program in Science and Technology in Sustainable Development, G.d\u2019Annunzio University, 66100 Chieti, Italy"},{"name":"Department of Innovative Technology in Medicine and Dentistry, G.d\u2019Annunzio University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Khuram","family":"Zakir","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pathology and Microbiology, Miulli Generale Hospital, LUM University, 70021 Acquaviva delle Fonti, Italy"},{"name":"PhD Program in Science and Technology in Sustainable Development, G.d\u2019Annunzio University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9725-1277","authenticated-orcid":false,"given":"Matteo","family":"Botteghi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, Universit\u00e0 Politecnica delle Marche, 60121 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-1665","authenticated-orcid":false,"given":"Francesco","family":"Gaudio","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Miulli Generale Hospital, LUM University, 70021 Acquaviva delle Fonti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Savio","sequence":"additional","affiliation":[{"name":"Research & Development Unit, R&D Solution Srl, 13030 Greggio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Martinotti","sequence":"additional","affiliation":[{"name":"PhD Program in Science and Technology in Sustainable Development, G.d\u2019Annunzio University, 66100 Chieti, Italy"},{"name":"Department of Innovative Technology in Medicine and Dentistry, G.d\u2019Annunzio University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7672-891X","authenticated-orcid":false,"given":"Stefano","family":"Martinotti","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pathology and Microbiology, Miulli Generale Hospital, LUM University, 70021 Acquaviva delle Fonti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Toniato","sequence":"additional","affiliation":[{"name":"Department of Innovative Technology in Medicine and Dentistry, G.d\u2019Annunzio University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders: DSM-5, American Psychiatric Association.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41380-018-0056-y","article-title":"The ASD Living Biology: From cell proliferation to clinical phenotype","volume":"24","author":"Courchesne","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/0300060517693423","article-title":"The role of oxidative stress, inflammation and acetaminophen exposure from birth to early childhood in the induction of autism","volume":"45","author":"Parker","year":"2017","journal-title":"J. Int. Med. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/aur.2696","article-title":"Global prevalence of autism: A systematic review update","volume":"15","author":"Zeidan","year":"2022","journal-title":"Autism Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13034-023-00673-0","article-title":"Autism spectrum disorder prevalence in Italy: A nationwide study promoted by the Ministry of Health","volume":"17","author":"Scattoni","year":"2023","journal-title":"Child Adolesc. Psychiatry Ment. Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/1362361318755318","article-title":"Factors associated with DSM-5 severity level ratings for autism spectrum disorder","volume":"23","author":"Mazurek","year":"2019","journal-title":"Autism"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e20193447","DOI":"10.1542\/peds.2019-3447","article-title":"Identification, evaluation, and management of children with autism spectrum disorder","volume":"145","author":"Hyman","year":"2020","journal-title":"Pediatrics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1542\/peds.2015-2851H","article-title":"Sleep difficulties and medications in children with autism spectrum disorders: A registry study","volume":"137","author":"Malow","year":"2016","journal-title":"Pediatrics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02791072.1981.10471447","article-title":"The religious and medicinal uses of Cannabis in China, India and Tibet","volume":"13","author":"Touw","year":"1981","journal-title":"J. Psychoact. Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1111\/bph.13186","article-title":"The role of cannabinoids in adult neurogenesis","volume":"172","author":"Prenderville","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zamberletti, E., Gabaglio, M., and Parolaro, D. (2017). The endocannabinoid system and autism spectrum disorders: Insights from animal models. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091916"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Fusar-Poli, L., Cavone, V., Tinacci, S., Concas, I., Petralia, A., Signorelli, M.S., D\u00edaz-Caneja, C.M., and Aguglia, E. (2020). Cannabinoids for people with ASD: A systematic review of published and ongoing studies. Brain Sci., 10.","DOI":"10.20944\/preprints202007.0373.v1"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Behl, T., Makkar, R., Sehgal, A., Singh, S., Makeen, H.A., Albratty, M., Alhazmi, H.A., Meraya, A.M., and Bungau, S. (2022). Exploration of multiverse activities of endocannabinoids in biological systems. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105734"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Parrella, N.-F., Hill, A.T., Enticott, P.G., Barhoun, P., Bower, I.S., and Ford, T.C. (2023). A systematic review of cannabidiol trials in neurodevelopmental disorders. Pharmacol. Biochem. Behav., 230.","DOI":"10.1016\/j.pbb.2023.173607"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jpsychires.2021.02.048","article-title":"Potential of cannabinoids as treatments for autism spectrum disorders","volume":"137","author":"Nezgovorova","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Robinson-Agramonte, M.d.L.A., Garc\u00eda, E.N., Guerra, J.F., Hurtado, Y.V., Antonucci, N., Sempr\u00fan-Hern\u00e1ndez, N., Schultz, S., and Siniscalco, D. (2022). Immune Dysregulation in Autism Spectrum Disorder: What Do We Know about It?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063033"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Erbescu, A., Papuc, S.M., Budisteanu, M., Arghir, A., and Neagu, M. (2022). Re-emerging concepts of immune dysregulation in autism spectrum disorders. Front. Psychiatry, 13.","DOI":"10.3389\/fpsyt.2022.1006612"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Su, T., Yan, Y., Li, Q., Ye, J., and Pei, L. (2021). Endocannabinoid system unlocks the puzzle of autism treatment via microglia. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.734837"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zou, M., Liu, Y., Xie, S., Wang, L., Li, D., Li, L., Wang, F., Zhang, Y., Xia, W., and Sun, C. (2021). Alterations of the endocannabinoid system and its therapeutic potential in autism spectrum disorder. Open Biol., 11.","DOI":"10.1098\/rsob.200306"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101194","DOI":"10.1016\/j.plipres.2022.101194","article-title":"Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities","volume":"89","author":"Mock","year":"2023","journal-title":"Prog. Lipid Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcp.2018.07.009","article-title":"The endocannabinoid system in mental disorders: Evidence from human brain studies","volume":"157","author":"Muguruza","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3934\/molsci.2019.1.27","article-title":"Endocannabinoid system involvement in autism spectrum disorder: An overview with potential therapeutic applications","volume":"6","author":"Schultz","year":"2019","journal-title":"AIMS Mol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s13311-022-01183-1","article-title":"An update on psychopharmacological treatment of autism spectrum disorder","volume":"19","author":"Aishworiya","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.pmbts.2020.04.016","article-title":"The role of the endocannabinoid system in autism spectrum disorders: Evidence from mouse studies","volume":"173","author":"Pietropaolo","year":"2020","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1017\/S0033291723002465","article-title":"The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses","volume":"53","author":"Hill","year":"2023","journal-title":"Psychol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13229-018-0203-y","article-title":"Plasma anandamide concentrations are lower in children with autism spectrum disorder","volume":"9","author":"Karhson","year":"2018","journal-title":"Mol. Autism"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13229-019-0256-6","article-title":"Lower circulating endocannabinoid levels in children with autism spectrum disorder","volume":"10","author":"Aran","year":"2019","journal-title":"Mol. Autism"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Hohmann, U., Pelzer, M., Kleine, J., Hohmann, T., Ghadban, C., and Dehghani, F. (2019). Opposite effects of neuroprotective cannabinoids, palmitoylethanolamide, and 2-arachidonoylglycerol on function and morphology of microglia. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.01180"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.neubiorev.2020.09.027","article-title":"Biochemical aspects and therapeutic mechanisms of cannabidiol in epilepsy","volume":"132","author":"Boleti","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17562864231207755","DOI":"10.1177\/17562864231207755","article-title":"Long-term efficacy and adverse effects of cannabidiol in adjuvant treatment of drug-resistant epilepsy: A systematic review and meta-analysis","volume":"16","author":"Liu","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_31","first-page":"4134","article-title":"Medical Cannabis sativa (Marijuana or Drug type); The story of discovery of \u03949-Tetrahydrocannabinol (THC)","volume":"5","author":"Malabadi","year":"2023","journal-title":"Int. J. Innov. Sci. Res. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/can.2015.0008","article-title":"Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment","volume":"1","author":"Wei","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/jnc.15321","article-title":"The neurochemistry of social reward during development: What have we learned from rodent models?","volume":"157","author":"Manduca","year":"2021","journal-title":"J. Neurochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s00213-022-06196-4","article-title":"Cannabidiol for the treatment of autism spectrum disorder: Hope or hype?","volume":"239","author":"Pedrazzi","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/cch.12909","article-title":"Medicinal cannabis in children and adolescents with autism spectrum disorder: A scoping review","volume":"48","author":"Fletcher","year":"2022","journal-title":"Child Care Health Dev."},{"key":"ref_36","first-page":"e20200149","article-title":"Cannabis and cannabinoid use in autism spectrum disorder: A systematic review","volume":"44","author":"Medeiros","year":"2021","journal-title":"Trends Psychiatry Psychother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8762","DOI":"10.1523\/JNEUROSCI.0708-19.2019","article-title":"Cannabidiol counteracts the psychotropic side-effects of \u03b4-9-tetrahydrocannabinol in the ventral hippocampus through bidirectional control of erk1\u20132 phosphorylation","volume":"39","author":"Hudson","year":"2019","journal-title":"J. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41386-022-01478-z","article-title":"Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD: THC ratios","volume":"48","author":"Englund","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2020.22.3\/vdimarzo","article-title":"The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders","volume":"22","year":"2020","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_41","first-page":"180","article-title":"Medicinal cannabis: History, pharmacology, and implications for the acute care setting","volume":"42","author":"Bridgeman","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10787-022-01020-z","article-title":"Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions","volume":"30","author":"Henson","year":"2022","journal-title":"Inflammopharmacology"},{"key":"ref_43","first-page":"372","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s42238-021-00108-7","article-title":"CBD-enriched cannabis for autism spectrum disorder: An experience of a single center in Turkey and reviews of the literature","volume":"3","author":"Bilge","year":"2021","journal-title":"J. Cannabis Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41398-022-02104-8","article-title":"Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: An open label study","volume":"12","author":"Hacohen","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: A proof-of-concept randomized trial","volume":"12","author":"Aran","year":"2021","journal-title":"Mol. Autism"},{"key":"ref_47","first-page":"44","article-title":"Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: Randomized, double-blind and controlled placebo clinical trial","volume":"26","author":"Medeiros","year":"2022","journal-title":"Trends Psychiatry Psychother."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Schleider, L.B.-L., Mechoulam, R., Sikorin, I., Naftali, T., and Novack, V. (2022). Adherence, safety, and effectiveness of medical cannabis and epidemiological characteristics of the patient population: A prospective study. Front. Med., 9.","DOI":"10.3389\/fmed.2022.827849"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1039\/C6NP00074F","article-title":"Phytocannabinoids: A unified critical inventory","volume":"33","author":"Meyer","year":"2016","journal-title":"Nat. Prod. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Berman, P., Futoran, K., Lewitus, G.M., Mukha, D., Benami, M., Shlomi, T., and Meiri, D. (2018). A new ESI-LC\/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-32651-4"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Campos, A.C., Foga\u00e7a, M.V., Scarante, F.F., Joca, S.R.L., Sales, A.J., Gomes, F.V., Sonego, A.B., Rodrigues, N.S., Galve-Roperh, I., and Guimar\u00e3es, F.S. (2017). Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00269"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Cifelli, P., Ruffolo, G., De Felice, E., Alfano, V., van Vliet, E.A., Aronica, E., and Palma, E. (2020). Phytocannabinoids in neurological diseases: Could they restore a physiological GABAergic transmission?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030723"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1360-0443.2009.02504.x","article-title":"Candidate genes for cannabis use disorders: Findings, challenges and directions","volume":"104","author":"Agrawal","year":"2009","journal-title":"Addiction"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.3390\/cimb45040228","article-title":"Cannabis pharmacogenomics: A path to personalized medicine","volume":"45","author":"Babayeva","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/can.2020.0154","article-title":"Safety and efficacy of medical cannabis in autism spectrum disorder compared with commonly used medications","volume":"7","author":"Holdman","year":"2022","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1007\/s11606-020-06504-8","article-title":"Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: A Comprehensive Review","volume":"36","author":"Balachandran","year":"2021","journal-title":"J. Gen. Intern. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cpt.2973","article-title":"Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants","volume":"114","author":"Bansal","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/FPC.0000000000000392","article-title":"PharmGKB summary: Sertraline pathway, pharmacokinetics","volume":"30","author":"Huddart","year":"2020","journal-title":"Pharmacogenetics Genom."},{"key":"ref_59","first-page":"29","article-title":"Adverse effects of cannabinoids","volume":"22","author":"Anciones","year":"2020","journal-title":"Epileptic Disord. Int. Epilepsy J. Videotape"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s42238-021-00073-1","article-title":"Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: Results of a modified Delphi process","volume":"3","author":"Bhaskar","year":"2021","journal-title":"J. Cannabis Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/imr.2022.0081","article-title":"The safety and effectiveness of commercially available cannabidiol products for health and well-being: A randomized, multi-arm, open-label waitlist-controlled trial","volume":"1","author":"Saleska","year":"2022","journal-title":"Integr. Med. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/19390211.2020.1765941","article-title":"Effects of hemp extract on markers of wellness, stress resilience, recovery and clinical biomarkers of safety in overweight, but otherwise healthy subjects","volume":"17","author":"Lopez","year":"2020","journal-title":"J. Diet. Suppl."},{"key":"ref_63","first-page":"100325","article-title":"The cannabidiol and marijuana research expansion act: Promotion of scientific knowledge to prevent a national health crisis","volume":"14","author":"Purcell","year":"2022","journal-title":"Lancet Reg. Health\u2014Am."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s43441-021-00346-0","article-title":"Real world evidence in medical cannabis research","volume":"56","author":"Banerjee","year":"2022","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"102935","DOI":"10.1016\/j.drugpo.2020.102935","article-title":"Access to cannabidiol without a prescription: A cross-country comparison and analysis","volume":"85","author":"McGregor","year":"2020","journal-title":"Int. J. Drug Policy"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Gidal, B.E., Vandrey, R., Wallin, C., Callan, S., Sutton, A., Saurer, T.B., and Triemstra, J.L. (2024). Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1335441"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/can.2020.0093","article-title":"Use and perceptions of cannabidiol products in Canada and in the United States","volume":"7","author":"Goodman","year":"2022","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_68","first-page":"285","article-title":"Pharmacology and legal status of cannabidiol","volume":"56","author":"Brunetti","year":"2020","journal-title":"Ann. Dell\u2019istituto Super. Sanit\u00e0"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"112600","DOI":"10.1016\/j.fct.2021.112600","article-title":"The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products","volume":"157","author":"Li","year":"2021","journal-title":"Food Chem. Toxicol."},{"key":"ref_70","unstructured":"US Department of Health and Human Services (2020). Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research-Guidance for Industry."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1186\/s13063-020-04862-6","article-title":"Clinical trials with cannabis medicines\u2014Guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: Considerations from the Australian experience","volume":"21","author":"Martin","year":"2020","journal-title":"Trials"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/1039856217715999","article-title":"Violence in severe mental illness: Is cognition missing in the associations with ethnicity, cannabis and alcohol?","volume":"25","author":"Giannouli","year":"2017","journal-title":"Australas. Psychiatry"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/22\/12453\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:35:47Z","timestamp":1760114147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/22\/12453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":72,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ijms252212453"],"URL":"https:\/\/doi.org\/10.3390\/ijms252212453","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]}}}